Find clinical trials for Triple Negative Breast Cancer in Cleveland, OH
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Triple Negative Breast Cancer trials near Cleveland, OH, USA:
This study will look to establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specif-...
Phase 2
Cleveland, Ohio, United States and 5 other locations
This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO)...
Phase 2
Cleveland, Ohio, United States and 13 other locations
with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...
Phase 3
Cleveland, Ohio, United States and 360 other locations
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...
Phase 3
Cleveland, Ohio, United States and 286 other locations
(HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative...
Phase 1
Cleveland, Ohio, United States and 39 other locations
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It wi ...
Phase 1
Cleveland, Ohio, United States and 23 other locations
The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standa...
Phase 1
Cleveland, Ohio, United States and 9 other locations
tumors....
Phase 1
Cleveland, Ohio, United States and 5 other locations
study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor...
Phase 1
Cleveland, Ohio, United States and 23 other locations
is to evaluate the safety of acasunlimab (also known as GEN1046) as monotherapy and in combination therapies in patients with malignant solid tumors...
Phase 1, Phase 2
Cleveland, Ohio, United States and 56 other locations
Clinical trials
Research sites
Resources
Legal